Citadel Advisors
BRNS

Citadel Advisors’s Barinthus Biotherapeutics BRNS Stock Holding History

Citadel Advisors’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.1K Buy
118,996
+197
+0.2% +$130 ﹤0.01% 12267
2025
Q4 		$83.2K Buy
+118,799
New +$119K ﹤0.01% 11773
2025
Q3 		– Sell
-16,227
Closed -$14.8K – 12814
2025
Q2 		$14.8K Sell
16,227
-9,945
-38% -$8.69K ﹤0.01% 12161
2025
Q1 		$25.9K Buy
+26,172
New +$26.9K ﹤0.01% 12941
2024
Q4 		– Sell
-27,717
Closed -$34.1K – 14535
2024
Q3 		$34.1K Buy
27,717
+11,680
+73% +$15.7K ﹤0.01% 12315
2024
Q2 		$22.5K Buy
+16,037
New +$36.2K ﹤0.01% 12537
2023
Q3 		– Sell
-14,877
Closed -$30.6K – 14313
2023
Q2 		$30.6K Buy
+14,877
New +$35.2K ﹤0.01% 12333
2023
Q1 		– Sell
-17,383
Closed -$41.5K – 14735
2022
Q4 		$41.5K Buy
+17,383
New +$44.3K ﹤0.01% 12367

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Citadel Advisors's BRNS Position: Q1 2026 in Review

Citadel Advisors increased its Barinthus Biotherapeutics (BRNS) stake by 0.17% in Q1 2026, buying an estimated $130 and bringing the position to 118,996 shares worth $68.1K. The position accounts for ﹤0.01% of the portfolio, ranked #12267.

Citadel Advisors first reported a position in BRNS in Q4 2022 and has held it in 8 quarters since. The position peaked at $83.2K in Q4 2025. 14 funds tracked by Wall St. Rank hold BRNS as of Q1 2026.

  • Citadel Advisors held 118,996 shares of Barinthus Biotherapeutics worth $68.1K as of Q1 2026.
  • Citadel Advisors bought 197 Barinthus Biotherapeutics shares in Q1 2026, an estimated $130.
  • Barinthus Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12267 holding.
  • Citadel Advisors first reported a position in Barinthus Biotherapeutics in Q4 2022 and has held it in 8 quarters since.
  • Citadel Advisors's Barinthus Biotherapeutics position peaked at $83.2K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.